Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

459.81 -3.46 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
63 64 Next >
Should you consider NASDAQ:VRTX for quality investing?
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
Vertex shares have climbed about 40% this year. 
Via The Motley Fool
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Better Growth Stock: Archer Aviation or Prime Medicine?
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
From Vertex Pharmaceuticals Incorporated
Via Business Wire
After This Landmark Win, Is CRISPR Therapeutics a Buy?
CRISPR Therapeutics stock already has advanced in the double digits this year. 
Via The Motley Fool
Why Vertex Stock Is Soaring Today
The drugmaker's non-opioid painkiller is showing promise in a select set of patients. 
Via The Motley Fool
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
CRISPR Therapeutics Just Made History. So Why Did Its Stock Fall?
The benefits from its first drug launch will trickle in slowly, at least at first. 
Via The Motley Fool
Here's the 1 Key Reason You Might Want to Buy CRISPR Therapeutics Stock on the Dip
This biotech could have more winners on the way. 
Via The Motley Fool
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better. 
Via InvestorPlace
Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review
The Dow hit a record high while the S&P 500 and Nasdaq set 2023 bests. 
Via Investor's Business Daily
Topics Economy Stocks
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
Via Investor Brand Network
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Small-Cap Stocks That Could Skyrocket 1000% by 2030
With the iShares Russell 2000 ETF (NYSE:IWM) on the move, investors should consider these small-cap stocks to buy. 
Via InvestorPlace
Topics ETFs
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700... 
Via Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage  
Via Benzinga
Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
The company tested an alternative to opioids and NSAIDs in patients with diabetic peripheral neuropathy. 
Via Investor's Business Daily
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks. 
Via InvestorPlace
1 Biotech Stock That Could Be the Next Amgen
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative
Vertex stock spiked early Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug. 
Via Investor's Business Daily
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. 
Via The Motley Fool
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.